Subscribe
shutterstock_555165064_kitreel
2 November 2022Big PharmaStaff Writer

Big pharma co buys $16.6bn for heart tech company

Johnson & Johnson (J&J) has agreed to acquire  Abiomed, a cardiovascular medical technology company, for $16.6 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More on this story

Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers